---
title: "Beyond Air, Inc. SEC 10-Q Report"
date: "2025-02-11 06:23:01"
summary: "Beyond Air, Inc., a medical device and biopharmaceutical company focused on the development and commercialization of innovative therapies for respiratory diseases, has released its latest Form 10-Q report. The report highlights significant financial improvements and key operational milestones achieved during the period. Financial Highlights Revenues: $2.553 million, reflecting an increase..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Beyond Air, Inc., a medical device and biopharmaceutical company focused on the development and commercialization of innovative therapies for respiratory diseases, has released its latest Form 10-Q report. The report highlights significant financial improvements and key operational milestones achieved during the period.

**Financial Highlights**

* **Revenues:** $2.553 million, reflecting an increase from $0.689 million in the prior year period, driven by the commercialization of LungFit® PH.
* **Gross Loss:** $(1.631) million, compared to $(0.794) million in the prior year period, indicating increased cost of revenues.
* **Loss from Operations:** $(37.363) million, compared to $(50.372) million in the prior year period, showing a reduction in operating expenses.
* **Net Loss:** $(40.416) million, compared to $(49.739) million in the prior year period, reflecting improved financial performance.
* **Net Basic and Diluted Loss Per Share:** $(0.64), compared to $(1.46) in the prior year period, indicating a decrease in loss per share due to increased shares outstanding.

**Business Highlights**

* **Revenue Segments:** The company reported revenue from the LungFit® PH device leases, which are accounted for as operating leases. The revenue from these leases was $1.1 million for the three months ended December 31, 2024, and $2.6 million for the nine months ended December 31, 2024.
* **Geographical Performance:** The company received European CE mark approval for the LungFit® PH system, which allows for the treatment of infants and adults with pulmonary hypertension in the EU. This approval is expected to enhance the company's market presence in Europe.
* **Sales Units:** The company has been actively leasing its LungFit® PH devices to hospitals and medical facilities, with a focus on increasing the number of units deployed to meet demand.
* **New Product Launches:** The company launched the LungFit® PH device in the United States for the treatment of persistent pulmonary hypertension of the newborn (PPHN) following FDA approval in June 2022.
* **Future Outlook:** The company plans to expand its LungFit® platform to address high unmet medical needs in severe lung infections, including nontuberculous mycobacteria (NTM) lung infection and chronic obstructive pulmonary disease (COPD). Additionally, the company is advancing its Beyond Cancer program, which targets solid tumors with ultra-high concentrations of gaseous nitric oxide (UNO), into phase 1 clinical trials.

SEC Filing: [Beyond Air, Inc. [ XAIR ] - 10-Q - Feb. 10, 2025](https://www.sec.gov/Archives/edgar/data/1641631/000149315225005678/form10-q.htm)

[TradingView](https://www.tradingview.com/news/tradingview:a09548b952054:0-beyond-air-inc-sec-10-q-report/)
